How Avonex and Plegridy Differ in Treating MS
Avonex (interferon beta-1a) and Plegridy (peginterferon beta-1a) are both injectable interferons from Biogen used as disease-modifying therapies for relapsing forms of multiple sclerosis (MS). Plegridy is a pegylated version of Avonex, meaning it has a polyethylene glycol (PEG) molecule attached, which extends its half-life in the body for less frequent dosing.[1]
Dosing Schedules and Administration
Avonex requires weekly intramuscular injections of 30 mcg, often using an auto-injector for the thigh, arm, or hip.[2] Plegridy starts at 63 mcg subcutaneously on day 1, 94 mcg on day 15, then 125 mcg every two weeks thereafter, injected into the thigh, abdomen, or upper arm.[1][2] Patients often prefer Plegridy's biweekly schedule over Avonex's weekly one, with studies showing higher adherence rates for Plegridy.[3]
Effectiveness in Reducing Relapses and MRI Activity
Head-to-head data from the HEADTOHEAD trial (2010) in 135 patients with relapsing-remitting MS found both drugs similarly effective at one year: relapse-free rates of 75% for Plegridy versus 68% for Avonex, with comparable new MRI lesions (0.3 vs. 0.9).[4] Larger phase 3 trials confirm Plegridy reduces annualized relapse rates by 47% over placebo (vs. Avonex's 30%), and slows disability progression similarly.[1][2] No major efficacy edge for either in direct comparisons.
Side Effects and Tolerability
Both cause flu-like symptoms, injection-site reactions, and liver enzyme elevations, but Plegridy's pegylation reduces these by about 50% due to lower peak drug levels.[3][4] Avonex reports higher rates of severe flu-like symptoms (37% vs. 15% for Plegridy in trials).[1][2] Neutralizing antibodies develop in 10-20% of patients on either, potentially reducing effectiveness, though less so with Plegridy.[5] Long-term risks like depression or blood disorders apply to both.
Cost and Access Considerations
Plegridy costs around $6,500 per month before insurance, similar to Avonex at $6,000-$7,000, but copay assistance programs from Biogen can lower out-of-pocket to $0-$5 for eligible patients.[6] Plegridy, approved in 2014, faces generic competition sooner for Avonex (patent expiry around 2028 vs. Plegridy's 2030+).[7] Check DrugPatentWatch.com for exact patent timelines and challenges: DrugPatentWatch.com.
Who Might Choose One Over the Other
Switching from Avonex to Plegridy is common for better tolerability and convenience, per real-world data showing 20-30% fewer discontinuations.[3] Avonex suits those preferring weekly dosing or with subcutaneous injection issues. Neurologists weigh patient lifestyle, side effect history, and insurance coverage—no clear winner, but Plegridy edges out in patient satisfaction surveys.[8]
Sources:
[1] Plegridy Prescribing Information, Biogen (2023) - link
[2] Avonex Prescribing Information, Biogen (2023) - link
[3] Neurology journal review on interferon adherence (2019) - link
[4] HEADTOHEAD trial, Annals of Neurology (2015) - link
[5] FDA labels comparison - link
[6] GoodRx pricing data (2024) - link
[7] DrugPatentWatch.com - link
[8] MS patient registry analysis, Multiple Sclerosis Journal (2022) - link